161 related articles for article (PubMed ID: 7945976)
1. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
Bräutigam K; Sohr R; Morgenstern R
Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
[TBL] [Abstract][Full Text] [Related]
2. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Blunt S; Jenner P; Marsden CD
Neuroscience; 1991; 40(2):453-64. PubMed ID: 1902916
[TBL] [Abstract][Full Text] [Related]
3. Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.
Blunt SB; Jenner P; Marsden CD
Exp Brain Res; 1992; 88(2):326-40. PubMed ID: 1577107
[TBL] [Abstract][Full Text] [Related]
4. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
5. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD
Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
7. Circling behavior in normoxic or hypoxic rats with unilateral 6-OHDA nigrostriatal lesion. Part 1. Effects of apomorphine and L-dopa.
Saligaut C; Daoust M; Moore N; Boismare F
Methods Find Exp Clin Pharmacol; 1987 Apr; 9(4):219-24. PubMed ID: 3110513
[TBL] [Abstract][Full Text] [Related]
8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
9. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
10. Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions.
Kashihara K; Manabe Y; Shiro Y; Warita H; Abe K
Neurosci Res; 2000 Nov; 38(3):273-9. PubMed ID: 11070194
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.
Sarre S; Herregodts P; Deleu D; Devrieze A; De Klippel N; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):277-85. PubMed ID: 1407014
[TBL] [Abstract][Full Text] [Related]
12. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
[TBL] [Abstract][Full Text] [Related]
13. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
14. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1998 Feb; 784(1-2):148-53. PubMed ID: 9518585
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
16. L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.
Ferre S; Casas M; Cobos A; Garcia C; Jane F; Grau JM
Psychopharmacology (Berl); 1987; 91(2):254-6. PubMed ID: 3107042
[TBL] [Abstract][Full Text] [Related]
17. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
Smith GA; Heuer A; Dunnett SB; Lane EL
Behav Brain Res; 2012 Jan; 226(1):281-92. PubMed ID: 21946310
[TBL] [Abstract][Full Text] [Related]
18. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Männistö PT; Tuomainen P
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
[TBL] [Abstract][Full Text] [Related]
19. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
20. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
